A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples